Estrogens affect endothelin-1 mRNA expression in LNCaP human prostate carcinoma cells

European Urology

Volumn 41, Issue 5, 2002, Pages 568-574

  Grande, Mirtha ^a   Carlström, Kjell ^b   Stege, Reinhard ^b   Pousette, Åke ^a   Faxén, Margareta ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Estrogen; ET 1; LNCaP FGC; LNCaP r; MRNA expression; Prostate cancer

Indexed keywords

ANDROGEN; COMPLEMENTARY DNA; ENDOTHELIN 1; ESTRADIOL; MESSENGER RNA; RNA; TESTOSTERONE;

ARTICLE; CANCER CELL; CANCER HORMONE THERAPY; DOSE TIME EFFECT RELATION; ESTROGEN METABOLISM; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CARCINOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0036586654     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0302-2838(02)00030-1     Document Type: Article

References (40)

1. Steg A. Is there still place for estrogens in the treatment of advanced prostatic carcinoma? In: Prostate cancer. Part B. Imaging techniques, radiotherapy, chemotherapy and management issues. New York: Raven Press, 1987. pp. 429–34.
2. K. Carlström R. Stege Testicular and adrenocortical function in men with prostatic cancer and in healthy age-matched controls Br. J. Urol. 79 1997 427 431
3. G.J. van Steenbrugge C.J. van Uffelen J. Bolt F.H. Schröder The human prostatic cancer cell line LNCaP and its derived sublines: An in vitro model for the study of androgen sensitivity J. Steroid Biochem. Mol. Biol. 40 1991 207 214
4. M. Hasenson B. Hartley-Asp C. Kihlfors A. Lundin J.Å. Gustafsson Å. Pousette Effect of hormones on growth and ATP content of a human prostatic carcinoma cell line, LNCaP-r Prostate 7 1985 183 194
5. G. Wilding M. Chen E.P. Gelmann Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens Prostate 14 1989 103 115
6. J. Veldscholte M.M. Voorhorst-Ogink J. Bolt-de Vries H.C. van Rooij J. Trapman E. Mulder Unusual specificity of the androgen receptor in the human prostate tumor cell line LNCaP: High affinity for progestagenic and estrogenic steroids Biochim. Biophys. Acta 1052 1990 187 194
7. A.L. Schuurmans J. Bolt J. Veldscholte E. Mulder Stimulatory effects of antiandrogens on LNCaP human prostate tumor cell growth, EGF-receptor level and acid phosphatase secretion J. Steroid Biochem. Mol. Biol. 37 1990 849 853
8. J. Veldscholte C.A. Berrevoets C. Ris-Stalpers G.G. Kuiper G. Jenster J. Trapman The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens J. Steroid Biochem. Mol. Biol. 41 1992 665 669
9. D.N. Grigoryev B.J. Long V.C.O. Njar A.H.M. Brodie Pregnenolone stimulates LNCaP prostate cancer cell growth via the mutated androgen receptor J. Steroid Biochem. Mol. Biol. 75 2000 1 10
10. A.L. Schuurmans J. Bolt M.M. Voorhorst R.A. Blankenstein E. Mulder Regulation of growth and epidermal growth factor receptor levels of LNCaP prostate tumor cells by different steroids Int. J. Cancer 42 1988 917 922
11. P. Ekman E.R. Barrack G.L. Greene E.V. Jensen P.C. Walsh Estrogen receptors in human prostate: Evidence for multiple binding sites J. Clin. Endocrinol. Metab. 57 1983 166 176
12. L.A. Castagnetta M.D. Miceli C.M. Sorci U. Pfeffer R. Farruggio G. Oliveri Growth of LNCaP human prostate cancer cells is stimulated by estradiol via its own receptor Endocrinology 136 1995 2309 2319
13. 2+ influx in LNCaP human prostate cancer Eur. J. Endocrinol. 135 1996 367 373
14. K.M. Lau M. LaSpina J. Long S.M. Ho Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: Regulation by methylation and involvement in growth regulation Cancer Res. 60 2000 3175 3182
15. J. Brolin L. Skoog P. Ekman Immunohistochemistry and biochemistry in detection of androgen, progesterone, and estrogen receptors in benign and malignant human prostatic tissue Prostate 20 1992 281 295
16. A. Hobisch A. Hittmair G. Daxenbichler S. Wille C. Radmayr P. Hobisch-Hagen Metastatic lesions from prostate cancer do not express oestrogen and progesterone receptors J. Pathol. 182 1997 356 361
17. B. Hanstein H. Liu M.C. Yancisin M. Brown Functional analysis of a novel estrogen receptor-β isoforms Mol. Edocrinol. 13 1999 129 137
18. M. Yanagisawa H. Kurihara S. Kimura Y. Tomobe M. Kobayashi Y. Mitsui A novel potent vasoconstrictor peptide produced by vascular endothelial cells Nature 332 1988 411 415
19. G.M. Rubanyi M.A. Polokoff Endothelins: Molecular biology, biochemistry, pharmacology, physiology, and pathophysiology Pharmacol. Rev. 46 1994 325 415
20. B. Battistini P. Chailler P. D’Orleans-Juste N. Briere P. Sirois Growth regulatory properties of endothelins Peptides 14 1993 385 399
21. A. Bagnato R. Tecce C. Moretti V. Di Castro D. Spergel K.J. Catt Autocrine actions of endothelin-1 as a growth factor in human ovarian carcinoma cells Clin. Cancer Res. 1 1995 1059 1066
22. J.B. Nelson S.P. Hedican D.J. George A.H. Reddi S. Piantadosi M.A. Eisenberger J.W. Simons Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate Nat. Med. 1 1995 944 949
23. J.B. Nelson K. Chan-Tack S.P. Hedican T.J. Opgenorth G.S. Bova J.W. Simons Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer Cancer Res. 56 1996 663 668
24. M. Shicheri Y. Hirata T. Nakajima K. Ando T. Imai M. Yanagisawa Endothelin-1 is an autocrine/paracrine growth factor for human cancer cells lines J. Clin. Invest. 87 1991 1867 1871
25. E.S. Grant T. Brown A. Roach B.C. Williams F.K. Habib In vitro expression of Endothelin-1 (ET-1) and the ETA and ETB ET receptors by the prostatic epithelium and stroma J. Clin. Endocrinol. Metab. 82 1997 508 513
26. T. Prayer-Galetti G.P. Rossi A.S. Belloni G. lbertin W. Battanello V. Piovan Gene expression and autoradiographic localization of endothelin-1 and its receptors A and B in the different zones of the normal human prostate J. Urol. 157 1997 2334 2339
27. C.S. Wingrove J.C. Stevenson 17β-Oestradiol inhibits stimulated endothelin release in human vascular endothelial cells Eur. J. Endocrinol. 137 1997 205 208
28. K. Carlström H. Sköldefors Ö. Tollbom Metabolism of estrone sulphate by benign prostatic hyperplasia in vitro Scand. J. Urol. Nephrol. 14 1980 135 137
29. M. Grande K. Carlström R. Stege Å. Pousette M. Faxén Estrogens increase the endothelial nitric oxide synthase (ecNOS) mRNA level in LNCaP human prostate carcinoma cells Prostate 45 2000 232 237
30. F. Pekonen T. Nyman E.M. Rutanen Differential expression of mRNAs for endothelin-related proteins in human endometrium, myometrium and leiomyoma Mol. Cell Endocrinol. 103 1994 165 170
31. D.L. Foss M.J. Baarsch M.P. Murtaugh Regulation of hypoxanthine phosphoribosyltransferase, glyceraldehyde-3-phosphate dehydrogenase and beta-actin mRNA expression in porcine immune cells and tissues Anim. Biotechnol. 9 1998 67 78
32. B.S. Lindberg P. Lindberg K. Martinsson E.D.B. Johansson Radioimmunological methods for the estimation of oestrone, oestradiol-17 beta and oestriol in pregnancy plasma Acta Obstet. Gynecol. Scand. 32 1974 5 19
33. K. Carlström R. Stege P. Henriksson M. Grande P.O. Gunnarsson Å. Pousette Possible bone-preserving capacity of high-dose intramuscular depot estrogen as compared to orchidectomy in the treatment of patients with prostatic carcinoma Prostate 31 1997 193 197
34. G. Carruba J. Adamski M. Calabro M.D. Miceli A. Cataliotti V. Bellavia Molecular expression of 17 beta hydroxysteroid dehydrogenase types in relation to their activity in intact human prostate cancer cells Mol. Cell Endocrinol. 131 1997 51 57
35. M. Hasenson B. Lundh B. Hartley-Asp Å. Pousette Growth inhibiting effect of estramustine on two prostatic carcinoma cell lines, LNCaP and LNCaP-r Urol. Res. 16 1988 357 361
36. M. Hasenson B. Hartley-Asp C. Kihlfors A. Lundin J.A. Gustafsson A. Pousette Effect of hormones on growth and ATP content of a human prostatic carcinoma cell line, LNCaP-r Prostate 7 1985 183 194
37. A. Hobisch J. Hoffmann L. Lambrinidis I.E. Eder G. Bartsch H. Klocker Z. Culig Antagonist/agonist balance of the nonsteroidal antiandrogen bicalutamide (casodex) in a new prostate cancer model Urol. Int. 65 2000 73 79
38. C.W. Gregory R.T. Johnson J.L. Mohler Jr. F.S. French E.M. Wilson Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen Cancer Res. 61 2001 2892 2898
39. M.J. Lilja K.J. Savinainen O.R. Saramäki T.L.J. Tammela R.L. Vessela T. Visakorpi Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer Cancer Res. 61 2001 3550 3555
40. A. Bagnato K.J. Catt Endothelins as autocrine regulators of tumor cell growth Trends Endocrin Met 9 1998 378 383